Last $1.63 USD
Change Today 0.00 / 0.00%
Volume 713.9K
GALE On Other Exchanges
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

galena biopharma inc (GALE) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/31/14 - $5.48
52 Week Low
01/7/15 - $1.43
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GALENA BIOPHARMA INC (GALE)

Related News

No related news articles were found.

galena biopharma inc (GALE) Related Businessweek News

No Related Businessweek News Found

galena biopharma inc (GALE) Details

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company’s lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical trials for the treatment of ovarian and endometrial cancers; and GALE-401 (Anagrelide CR), which has completed Phase I studies for the treatment of essential thrombocythemia. Galena Biopharma, Inc. has strategic partnership with Dr. Reddy's Laboratories Ltd. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Portland, Oregon.

60 Employees
Last Reported Date: 03/17/14
Founded in 2003

galena biopharma inc (GALE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $490.0K
Chief Financial Officer, Vice President and C...
Total Annual Compensation: $236.0K
Compensation as of Fiscal Year 2013.

galena biopharma inc (GALE) Key Developments

Galena Biopharma Hires Joseph Lasaga as Vice President, Business Development and Alliance Management

Galena Biopharma, Inc. announced it has hired Joseph Lasaga as Vice President, Business Development and Alliance Management, reporting to the President and CEO. Mr. Joseph Lasaga has more than 17 years of experience in the biotechnology and pharmaceutical industry in the areas of research and development, business development, alliance management and product strategy. Prior to joining Galena, Mr. Lasaga spent four years at Nektar Therapeutics, most recently as Senior Director, Business Development.

Galena Biopharma Provides Revenue Guidance for the Year 2014 and for the Year 2015

Galena Biopharma provided revenue guidance for the year 2014 and for the year 2015. For the year 2014, revenue in line with expectations and an outlook for 2015 that falls short of the consensus in an update of milestones expected for this year. The biopharmaceutical company expects 2014 revenue in the middle of its range of $8 million to $10 million after having its best quarter to date for sales in fourth quarter. For 2015, the company expects revenue of $15 million to $18 million and expects its Abstral sublingual tablets for cancer pain to become accretive this year.

Galena Biopharma, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:00 PM

Galena Biopharma, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:00 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Mark W. Schwartz, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALE:US $1.63 USD 0.00

GALE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.77 AUD +0.015
BioDelivery Sciences International Inc $13.10 USD -0.53
Prosensa Holding NV $18.74 USD +0.06
Silence Therapeutics PLC 222.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$32.68 CAD -0.22
View Industry Companies

Industry Analysis


Industry Average

Valuation GALE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.5x
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENA BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at